Hépato-Gastro & Oncologie Digestive


What is the next 5-year future for pancreatic cancer medical treatment? Volume 22, issue 6, Juin 2015


  • Figure 1

  • Figure 2


1 Hôpitaux Universitaires Paris Nord Val de Seine (HUPNVS),
Hôpital Beaujon,
service d’oncologie digestive,
Université Paris 7 - Denis Diderot,
100 boulevard du Général Leclerc,
92110 Clichy La Garenne, France
2 Hôpital Henri Mondor,
service d’oncologie médicale,
51 avenue du Maréchal de Lattre de Tassigny,
94010 Créteil, France
3 Hôpital Universitaire Necker-Enfants Malades,
département de pharmacologie clinique,
149 rue de Sèvres, 75743 Paris, France
4 AAREC Filia Research,
département de recherche translationnelle,
1 place Paul Verlaine,
92100 Boulogne-Billancourt, France
* Tirés à part

Therapeutic options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited. Gemcitabine has been the standard chemotherapy until 2011, when the FOLFIRINOX regimen (combining 5-FU, irinotecan, and oxaliplatine) and then the gemcitabine plus nab-paclitaxel regimen demonstrated a survival benefit over gemcitabine alone in metastatic PDAC. Despite these significant achievements, new therapeutic options for advanced PDAC are crucially needed. Most of the « targeted » therapies that have shown efficacy in other cancer types did not yield significant survival benefit in advanced PDAC patients. A better understanding of the molecular and cellular mechanisms of pancreatic carcinogenesis, as well as its microenvironment has led to the development of innovant concepts and alternative therapeutic strategies. Some of them have shown promising results. The aim of this review is to provide an overview of these recent advances and try to draw a five year forward view of the future of PDAC therapy.